Analyzing Cybin (CYBN) & Its Competitors

Cybin (NYSE:CYBN) is one of 444 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Cybin to similar businesses based on the strength of its institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Risk and Volatility

Cybin has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Cybin’s competitors have a beta of 1.26, indicating that their average share price is 26% more volatile than the S&P 500.

Institutional and Insider Ownership

17.9% of Cybin shares are held by institutional investors. Comparatively, 29.6% of shares of all “Biotechnology” companies are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 25.7% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Cybin and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cybin	N/A	-$35.93 million	-44.15
Cybin Competitors	$148.01 million	-$13.29 million	146.72

Cybin’s competitors have higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Cybin and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0	0	3	0	3.00
Cybin Competitors	735	2180	5106	56	2.56

Cybin currently has a consensus price target of $50.50, indicating a potential upside of 471.91%. As a group, “Biotechnology” companies have a potential upside of 10.68%. Given Cybin’s stronger consensus rating and higher possible upside, research analysts plainly believe Cybin is more favorable than its competitors.

Profitability

This table compares Cybin and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-109.05%	-97.85%
Cybin Competitors	-8,581.07%	-107.97%	-23.29%

Summary

Cybin competitors beat Cybin on 9 of the 13 factors compared.

About Cybin

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.